v3.26.1
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating expenses:    
Research and development $ 4,552 $ 2,800
General and administrative 4,729 2,221
Total operating expenses 9,281 5,021
Loss from operations (9,281) (5,021)
Other income (expense):    
Change in fair value of warrant derivative 0 230
Foreign exchange loss (6) (37)
Interest income 44 117
Total other income, net 38 310
Net loss (9,243) (4,711)
Other comprehensive loss:    
Translation adjustments 0 110
Comprehensive loss $ (9,243) $ (4,601)
Basic net loss per share (in dollars per share) $ (0.08) $ (0.06)
Diluted net loss per share (in dollars per share) $ (0.08) $ (0.06)
Weighted average common shares outstanding - basic (in shares) 112,292,579 84,631,445
Weighted average common shares outstanding - diluted (in shares) 112,292,579 84,631,445